Mirum Pharmaceuticals Posts 49.8% Q4 Revenue Growth to $148.9M, EPS Loss Narrows
Mirum Pharmaceuticals delivered Q4 revenue of $148.93 million, up 49.8% year-over-year and 5.4% ahead of estimates, while EPS improved to a loss of $0.11 from -$0.49 a year ago but fell short of the $0.02 target. Livmarli sales reached $106.39 million versus $98.37 million expected.
1. Q4 Financial Results
Mirum Pharmaceuticals reported fourth-quarter revenue of $148.93 million, marking a 49.8% year-over-year increase and beating consensus by 5.4%. The company posted a non-GAAP loss per share of $0.11, an improvement from a $0.49 loss a year ago but below the $0.02 profit estimate.
2. Segment Sales Performance
Total product sales net matched $148.93 million against a $142.62 million estimate. Bile acid medicines generated $42.55 million versus a $42.58 million forecast, while Livmarli revenue reached $106.39 million, topping the $98.37 million consensus.
3. Stock Reaction and Outlook
Shares have risen 8.3% over the past month following the results, with the company holding a neutral market rank. Future momentum will depend on management’s guidance and upcoming quarterly forecasts amid ongoing investment in rare-disease therapies.